News:
Front Page |
National |
Tamil Nadu |
Andhra Pradesh |
Karnataka |
Kerala |
New Delhi |
Other States |
International |
Opinion |
Business |
Sport |
Miscellaneous |
Advts:
Classifieds |
Employment |
Obituary |
Business
-
Briefly
Shreya Life Sciences' plans
HYDERABAD: The Rs. 180 crore Mumbai based Shreya Life Sciences has chalked out ambitious plans to achieve a turnover of Rs. 200 crores next year and a quantum jump to Rs. 500 crores by March 2006. They hope to achieve this using the route of acquisitions and line extension, according to Amitava Sengupta, National Head of Sales. Addressing a press conference here on Tuesday, he said the company had acquired the pharmaceutical division of Rallis India (a Tata Enterprise) in 2001, and Indore based Ethico and Plethico six months ago. Its new Pune facility would be ready by mid-2005 to produce human insulin and novel drug delivery, and hepatitis B vaccine. It is now strong in gastro intestinal care (GI Care), pain management and nutritional range, with gastro drugs accounting for 33 per cent of revenues. These were also the segments in which they were looking for acquisitions, he said. The company also launched its latest offering `Tadalafil' here on Tuesday. — Our Special Correspondent
Printer friendly
page
Send this article to Friends by
E-Mail
Business
News:
Front Page |
National |
Tamil Nadu |
Andhra Pradesh |
Karnataka |
Kerala |
New Delhi |
Other States |
International |
Opinion |
Business |
Sport |
Miscellaneous |
Advts:
Classifieds |
Employment |
Obituary |
Updates:
Breaking News |
|
